World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 11 January 2021
Main ID:  EUCTR2015-001275-50-IT
Date of registration: 05/11/2020
Prospective Registration: No
Primary sponsor: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
Public title: Effects of abatacept in patients who have recently been diagnosed with rheumatoid arthritis.
Scientific title: A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive - ND
Date of first enrolment: 17/12/2015
Target sample size: 1500
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001275-50
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Australia Austria Brazil Canada Chile Colombia Czech Republic
Czechia Finland France Germany Hungary Israel Italy Japan
Korea, Democratic People's Republic of Korea, Republic of Mexico Netherlands Peru Poland Qatar Romania
Russian Federation Saudi Arabia Singapore South Africa Spain Sweden Taiwan United Arab Emirates
United Kingdom
Contacts
Name: GCT-SU   
Address:  Parc de l'Alliance - Avenue de Finlande, 4 1420 Braine-l'Alleud Belgium
Telephone: 000000
Email: clinical.trials@bms.com
Affiliation:  Bristol-Myers Squibb International Corporation
Name: GCT-SU   
Address:  Parc de l'Alliance - Avenue de Finlande, 4 1420 Braine-l'Alleud Belgium
Telephone: 000000
Email: clinical.trials@bms.com
Affiliation:  Bristol-Myers Squibb International Corporation
Key inclusion & exclusion criteria
Inclusion criteria:
a) Subjects have early RA, defined as diagnosis made by the ACR/EULAR
2010 criteria for the classification of RA within the past 6 months
b) Subjects must meet at least one of the following criteria:
i) CRP > 0.3mg/dL (ULN)
ii) ESR= 28mm/hr
c) Subjects have at least 3 tender joints and at least 3 swollen joints
using the 28 Joint Count Assessment at both screening and Day 1
(Appendix 11)
d) Subjects are positive for anti-citrullinated protein antibodies (ACPA)
e) Subjects have an SDAI > 11
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1350
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 150

Exclusion criteria:
a) Subjects at risk for tuberculosis
b) Subjects with recent acute infection
c) Subjects with history of chronic or recurrent bacterial, viral or
systemic fungal infections.
d) Subjects who have present or previous malignancies, except
documented history of cured non-metastatic squamous or basal skin cell
carcinoma, or cervical carcinoma in situ
e) Creatinine clearance < 40 mL/min (Cockroft-Gault formula)


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Early Rheumatoid Arthritis
MedDRA version: 23.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Intervention(s)

Product Name: Abatacept
Product Code: [BMS-188667]
Pharmaceutical Form: Solution for injection
INN or Proposed INN: ABATACEPT
CAS Number: 332348-12-6
Current Sponsor code: BMS-188667
Other descriptive name: ND
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Trade Name: Methotrexate Ebewe
Product Name: Methotrexate
Product Code: [na]
Pharmaceutical Form: Tablet
INN or Proposed INN: METHOTREXATE
Current Sponsor code: na
Other descriptive name: METHOTREXATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-

Trade Name: Methotrexate Ebewe
Product Name: Methotrexate
Product Code: [na]
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: METOTREXATO
Current Sponsor code: nd
Other descriptive name: METHOTREXATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Primary Outcome(s)
Main Objective: The primary objective for this study is to compare the clinical efficacy of
weekly abatacept in combination with MTX to MTX alone in achieving
Remission, defined as SDAI = 3, at Week 24.
Primary end point(s): The primary efficacy endpoint is the proportion of subjects in SDAI Remission at Week 24.
Secondary Objective: 1) To compare the efficacy of weekly abatacept + MTX to MTX alone in
achieving remission by DAS28-CRP Remission criteria at Week 24.
2) To compare the efficacy of weekly abatacept + MTX to MTX alone in
achieving remission by SDAI remission criteria at Week 52.
3) To compare the efficacy of weekly abatacept + MTX to MTX alone in
reducing joint damage by X-ray at Week 52.
4) To compare the efficacy of weekly abatacept + MTX to MTX alone in
achieving remission by Boolean remission criteria at Week 52.
Timepoint(s) of evaluation of this end point: Week 24
Secondary Outcome(s)
Secondary end point(s): The secondary endpoints below will be assessed in the order below in a
hierarchical fashion after the primary endpoint is met to preserve the
type I error of the study at 5%
(1) Proportion of subjects in DA28-CRP Remission at Week 24
(2) Proportion of subjects in SDAI Remission at Week 52
(3) Mean change from baseline in TSS at Week 52
(4) Proportion of subjects in Boolean Remission at Week 52
Timepoint(s) of evaluation of this end point: (1) Week 24
(2) Week 52
(3) Week 52
(4) Week 52
Secondary ID(s)
2015-001275-50-CZ
IM101-550
ISRCTN00000000
NCT00000000
Source(s) of Monetary Support
Bristol-Myers Squibb International Corporation
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 17/12/2015
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history